This story originally appeared on Zacks
Precision BioSciences (DTIL) closed the most recent trading day at $4.28, moving -1.83% from the previous trading session. This change lagged the S&P 500’s daily gain of 2.24%. At the same time, the Dow added 2.51%, and the tech-heavy Nasdaq lost 0.17%.
Heading into today, shares of the genome editing company had gained 2.59% over the past month, outpacing the Medical sector’s loss of 1% and the S&P 500’s loss of 2.58% in that time.
Precision BioSciences will be looking to display strength as it nears its next earnings release. In that report, analysts expect Precision BioSciences to post earnings of -$0.50 per share. This would mark a year-over-year decline of 13.64%. Meanwhile, our latest consensus estimate is calling for revenue of $8.24 million, down 6.86% from the prior-year quarter.
It is also important to note the recent changes to analyst estimates for Precision BioSciences. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company’s business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Precision BioSciences is currently a Zacks Rank #3 (Hold).
The Medical – Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 150, which puts it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Just Released: Zacks Top 10 Stocks for 2022
In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2022?
From inception in 2012 through 2021, the Zacks Top 10 Stocks portfolios gained an impressive +1,001.2% versus the S&P 500’s +348.7%. Now our Director of Research has combed through 4,000 companies covered by the Zacks Rank and has handpicked the best 10 tickers to buy and hold. Don’t miss your chance to get in…because the sooner you do, the more upside you stand to grab.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Precision BioSciences, Inc. (DTIL): Free Stock Analysis Report
To read this article on Zacks.com click here.